Pergolide Eye Drops for Corneal Nerve Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular chemical burns, such as chemical injuries to the eye, are inadequate in regenerating corneal tissue and managing neuropathic ocular pain, with existing methods like autologous or allogeneic serum eye drops being challenging to obtain and not fully effective in promoting nerve regeneration.
Innovation Solution
Topical administration of pergolide, a dopamine receptor agonist, as an eye drop formulation, which has been shown to improve corneal nerve regeneration and reduce corneal haze in a mouse model of traumatic corneal alkali injury.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If standard treatment (prophylactic antibiotics, vitamin C, lubricating eye drops) is used, then temporary pain relief is provided, but corneal tissue regeneration is not achieved
Solution Approach 1:
The patent changes the pharmacological parameter by introducing pergolide, a dopamine receptor agonist, which activates neurotrophic pathways to promote corneal nerve regeneration and tissue healing, transforming the treatment outcome from temporary symptom relief to actual tissue regeneration
Solution Approach 2:
Pergolide acts as an intermediary substance that bridges the gap between standard supportive care and effective regenerative therapy, utilizing dopamine receptor activation to stimulate endogenous neurotrophic factors and accelerate corneal healing
2Object-affected harmful factors
If topocal corticosteroids are used, then inflammation is controlled, but corneal healing is hindered
Solution Approach 1:
Pergolide serves as an intermediary that promotes corneal healing without the harmful side effects of corticosteroids, utilizing dopamine receptor activation to stimulate neurotrophic factor release and accelerate tissue regeneration while avoiding immunosuppression-related healing delays
3Reliability
If autologous or allogeneic serum eye drops are used, then neural regeneration is promoted, but the treatment is challenging to obtain and not fully effective
Solution Approach 1:
The patent replaces complex, difficult-to-obtain serum products with pergolide, a stable, easily administered pharmaceutical compound that can be formulated as simple eye drops, eliminating the need for blood draws and serum processing while maintaining neuroregenerative efficacy
Solution Approach 2:
The invention changes the delivery parameter from complex serum-based therapy to a simple pergolide solution that can be easily administered as eye drops, transforming the treatment from difficult-to-obtain to readily available while maintaining or improving neuroregenerative effectiveness
4Reliability
If pergolide is administered topically, then corneal nerve regeneration is improved, but the mechanism was not previously established
Solution Approach 1:
Pergolide acts as an intermediary that activates dopamine receptors on corneal nerves, triggering the release of neurotrophic factors such as NGF and BDNF, which then promote nerve regeneration and restore corneal sensitivity
Solution Approach 2:
The patent replaces the need for complex serum-based neuroregenerative therapy with a simpler pergolide mechanism that directly activates dopamine receptors, eliminating the need for blood products and complex formulation while achieving the same or better regenerative outcomes
Data Source
AI summary
Chemical injuries to the eye can cause permanent vision impairment or blindness, as well as chronic pain and dry eye syndrome. Disclosed herein is a method of treating an ocular chemical burn by administering an effective amount of pergolide to an eye of a subject, such as via a topical formulation. Further disclosed are compositions and kits used for that treatment, such as pergolide solutions, and pergolide eye drop formulations.